27Jul 2022
Safety and Efficacy of Istaroxime for Patients with Acute‐Heart‐Failure‐Related Pre‐cardiogenic Shock ‐ A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel Group Study (SEISMiC)

Safety and Efficacy of Istaroxime for Patients with Acute‐Heart‐Failure‐Related Pre‐cardiogenic Shock ‐ A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel Group Study (SEISMiC)

The study examined the effects of istaroxime in patients hospitalized for acute heart failure (AHF) related to the Society for Cardiovascular Angiography and Interventions (SCAI) stage B pre‐cardiogenic shock (CS). Sixty patients with AHF without acute myocardial infarction with pre‐CS, defined as systolic blood pressure (SBP) < 90 mmHg without hypoperfusion, venous lactate > 2 mmol/L and/or mechanical or inotropic support, were randomized to istaroxime 1.0 ‐1.5 μg/kg/min or placebo for 24 hours. In phase 2a study of patients with AHF related pre‐CS istaroxime improved BP and some echocardiography measures associated with HF and were well tolerated.

  • #cardiology

Like

Save

Share